1. AN IMPROVED BENEFIT‐RISK PROFILE OF DUVELISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA WHO RECEIVED 2 OR MORE PRIOR THERAPIES. (12th June 2019) Authors: Flinn, I.W.; Davids, M.S.; Hillmen, P.; Montillo, M.; Delgado, J.; Kuss, B.J.; Tam, C.S.; Jäger, U.; Ghia, P.; Stilgenbauer, S.; Lustgarten, S.; Weaver, D.T.; Youssoufian, H.; Cymbalista, F. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 213 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. EFFECT OF DOSE MODIFICATIONS ON RESPONSE TO DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY CLL/SLL IN THE DUO TRIAL. (12th June 2019) Authors: Ghia, P.; Flinn, I.W.; Lamanna, N.; Montillo, M.; Illés, Á.; Etienne, G.; Delgado, J.; Kuss, B.J.; Tam, C.S.; Offner, F.; Bosch, F.; Davids, M.S.; Jäger, U.; Cymbalista, F.; Weaver, D.T.; Lustgarten, S.; Youssoufian, H.; Stilgenbauer, S. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 214 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Fatty intra‐abdominal lymph nodes in chronic lymphocytic leukemia. Issue 2 (February 2014) Authors: Cooley, C.L.; Davids, M.S.; Giardino, A. Journal: American journal of hematology Issue: Volume 89:Issue 2(2014:Feb.) Page Start: 234 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. INITIAL RESULTS OF A MULTICENTER PHASE 2 STUDY OF VENETOCLAX IN COMBINATION WITH DOSE‐ADJUSTED R‐EPOCH FOR PATIENTS WITH RICHTER'S SYNDROME (CRC‐043). (12th June 2019) Authors: Davids, M.S.; Thompson, P.A.; Rogers, K.A.; Tyekucheva, S.; Pazienza, S.; Francoeur, K.; Renner, S.K.; Bazemore, J.; Rocchio, M.; Ihuoma, U.; Jacobson, C.A.; Fisher, D.C.; Brown, J.R. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 134 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. PATTERNS OF DUVELISIB‐INDUCED LYMPHOCYTOSIS IN PATIENTS WITH R/R CLL OR SLL INCLUDING THOSE WITH HIGH‐RISK FACTORS TREATED IN THE DUO TRIAL. (12th June 2019) Authors: Barrientos, J.; Flinn, I.; Davids, M.S.; Cashen, A.; Chiorazzi, N.; Chen, S.; Hidy, S.; Pachter, J.; Lustgarten, S.; Weaver, D.T.; Brown, J. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 216 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. THE COMBINATION OF VENETOCLAX AND IBRUTINIB IS EFFECTIVE IN RELAPSED/REFRACTORY T‐PROLYMPHOCYTIC LEUKEMIA AND INFLUENCES BCL‐2‐FAMILY MEMBER DEPENDENCIES. (12th June 2019) Authors: Kornauth, C.F.; Herbaux, C.; Boidol, B.; Guillemette, C.; Mayerhöfer, M.E.; Jäger, U.; Kubicek, S.; Davids, M.S.; Staber, P.B. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 482 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. UPDATED RESULTS OF A MULTICENTER PHASE I/IB STUDY OF TGR‐1202 IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY MCL OR CLL. (June 2017) Authors: Davids, M.S.; Kim, H.T.; Nicotra, A.; Savell, A.; Francoeur, K.; Hellman, J.M.; Miskin, H.; Sportelli, P.; Bashey, A.; Stampleman, L.; Rueter, J.; Boruchov, A.; Arnason, J.E.; Jacobson, C.A.; Jacobsen, E.J.; Fisher, D.C.; Brown, J.R. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 54 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. VENETOCLAX (VEN) IN PATIENTS WITH RELAPSED/REFRACTORY NON‐HODGKIN LYMPHOMA (NHL). (June 2017) Authors: Davids, M.S.; Roberts, A.W.; Seymour, J.F.; Wierda, W.G.; Puvvada, S.D.; Gressick, L.; Alter, D.; Dunbar, M.; Zhou, L.; Kim, S.; Verdugo, M.; Gerecitano, J.F. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 203 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗